Answers are grounded in this paper and cite their sources.
Breast cancer exhibits substantial subtype‑ and stage‑dependent immunological heterogeneity, resulting in unequal sensitivity to programmed cell death protein 1/programmed death‑ligand 1 (PD‑L1) blockade. In triple‑negative breast cancer, pembrolizumab‑based therapy has an established role in high‑risk early disease and in PD‑L1+ advanced disease, whereas the evidence in HER2+ and hormone receptor+/HER2‑ breast cancer remains more context‑dependent and is largely investigational. The present structured narrative review integrates breast cancer‑specific evidence across four interrelated topics, which comprise the molecular regulation of PD‑L1, subtype‑specific clinical translation, the mechanisms underlying primary, adaptive and acquired resistance and the standardization of biomarkers and assays. It distinguishes mechanisms directly demonstrated in breast cancer from those extrapolated from other malignancies and organizes therapeutic strategies according to evidence maturity. Consideration is given to the fact that PD‑L1 assays and scoring systems are not interchangeable, to the limitations of complementary biomarkers and to the emergence of antibody‑drug conjugate‑checkpoint inhibitor combinations. The literature is organized according to subtype, disease setting, biomarker and level of evidence to distinguish established clinical practice from investigational and preclinical approaches and to identify priorities for precision immunotherapy in breast cancer.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: